89,113 Danaher Corporation $DHR Shares Acquired by Fisher Asset Management LLC

Key Points

• Fisher Asset Management increased its Danaher stake by 2.0% in the third quarter, buying 89,113 shares to hold about 4.57 million shares, valued at roughly $1.01 billion. Institutional investors and hedge funds own 79.05% of the stock.
• Danaher reported quarterly EPS of $2.11, above analysts’ $1.92 estimate; revenue rose 8.3% year over year to $6.55 billion, slightly below expectations.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $242.91. The company also paid a quarterly dividend of $0.40 per share, equivalent to a 0.7% yield.

Fisher Asset Management LLC grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,573,887 shares of the conglomerate's stock after buying an additional 89,113 shares during the quarter. Fisher Asset Management LLC owned about 0.65% of Danaher worth $1,013,345,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in DHR. Eurizon Capital SGR S.p.A. boosted its stake in Danaher by 16.8% during the third quarter. Eurizon Capital SGR S.p.A. now owns 284,412 shares of the conglomerate's stock valued at $63,120,000 after buying an additional 41,003 shares in the last quarter. Nan Fung Trinity HK Ltd. raised its holdings in shares of Danaher by 150.5% during the third quarter. Nan Fung Trinity HK Ltd. now owns 171,200 shares of the conglomerate's stock valued at $37,929,000 after acquiring an additional 102,865 shares during the period. Van Strum & Towne Inc. acquired a new stake in Danaher during the 3rd quarter valued at $217,000. Three Bridge Wealth Advisors LLC acquired a new position in Danaher during the third quarter valued at $55,000. Finally, Schwallier Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter valued at about $229,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 1.4%

Shares of NYSE DHR opened at $232.08 on Friday. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a market cap of $163.28 billion, a price-to-earnings ratio of 37.98, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The firm's 50-day simple moving average is $222.11 and its 200 day simple moving average is $201.53.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same period in the prior year, the business earned $1.89 earnings per share. Danaher's quarterly revenue was up 8.3% on a year-over-year basis. On average, research analysts expect that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date was Wednesday, September 30th. Danaher's payout ratio is 26.19%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Barclays increased their price objective on Danaher from $255.00 to $260.00 and gave the stock an "overweight" rating in a report on Thursday, October 22nd. Royal Bank Of Canada raised their price objective on Danaher from $215.00 to $250.00 and gave the company an "outperform" rating in a research note on Monday, October 5th. Weiss Ratings raised shares of Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. Guggenheim upped their price target on Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Finally, Robert W. Baird raised their price objective on Danaher from $246.00 to $254.00 and gave the stock an "outperform" rating in a research report on Thursday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $242.91.

Insider Buying and Selling at Danaher

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of the stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total value of $1,782,186.88. Following the transaction, the chief accounting officer directly owned 9,107 shares in the company, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregory Milosevich sold 2,100 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $5,158,277.54. The trade was a 8.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 10.80% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company's businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.